Bioaffinity Technologies, Stock Buy Hold or Sell Recommendation
| BIAF Stock | USD 0.37 0.02 5.71% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding bioAffinity Technologies, is 'Strong Sell'. Macroaxis provides BioAffinity Technologies, buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding BIAF positions.
Check out BioAffinity Technologies, Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in BioAffinity Stock please use our How to Invest in BioAffinity Technologies, guide. Note, we conduct extensive research on individual companies such as BioAffinity and provide practical buy, sell, or hold advice based on investors' constraints. bioAffinity Technologies,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
BioAffinity |
Execute BioAffinity Technologies, Buy or Sell Advice
The BioAffinity recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on bioAffinity Technologies,. Macroaxis does not own or have any residual interests in bioAffinity Technologies, or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute BioAffinity Technologies,'s advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Extremely Dangerous | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
BioAffinity Technologies, Trading Alerts and Improvement Suggestions
| BioAffinity Technologies, generated a negative expected return over the last 90 days | |
| BioAffinity Technologies, has high historical volatility and very poor performance | |
| BioAffinity Technologies, has some characteristics of a very speculative penny stock | |
| BioAffinity Technologies, has a very high chance of going through financial distress in the upcoming years | |
| bioAffinity Technologies, currently holds 1.58 M in liabilities. bioAffinity Technologies, has a current ratio of 0.02, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about BioAffinity Technologies,'s use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 2.53 M. Net Loss for the year was (7.94 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| bioAffinity Technologies, currently holds about 214.4 K in cash with (6.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08. | |
| Roughly 30.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Anderson Robert A. of 33784 shares of BioAffinity Technologies, subject to Rule 16b-3 |
BioAffinity Technologies, Returns Distribution Density
The distribution of BioAffinity Technologies,'s historical returns is an attempt to chart the uncertainty of BioAffinity Technologies,'s future price movements. The chart of the probability distribution of BioAffinity Technologies, daily returns describes the distribution of returns around its average expected value. We use bioAffinity Technologies, price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of BioAffinity Technologies, returns is essential to provide solid investment advice for BioAffinity Technologies,.
| Mean Return | -1.26 | Value At Risk | -16.1 | Potential Upside | 13.46 | Standard Deviation | 7.64 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of BioAffinity Technologies, historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
BioAffinity Stock Institutional Investors
| Shares | Tower Research Capital Llc | 2024-12-31 | 6.3 K | Oarsman Capital, Inc | 2024-12-31 | 2.4 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 500 | Clear Street Llc. | 2024-09-30 | 100.0 | Bank Of America Corp | 2024-12-31 | 84.0 | Jpmorgan Chase & Co | 2024-12-31 | 21.0 | Ground Swell Capital, Llc | 2024-09-30 | 0.0 | Ubs Group Ag | 2024-09-30 | 0.0 | Renaissance Technologies Corp | 2024-09-30 | 0.0 | Vanguard Group Inc | 2024-12-31 | 260.9 K | Geode Capital Management, Llc | 2024-12-31 | 99.6 K |
BioAffinity Technologies, Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | (495.4K) | 1.3M | 10.1M | (8.6M) | (7.7M) | (7.3M) | |
| Free Cash Flow | (2.2M) | (2.0M) | (4.3M) | (6.1M) | (5.5M) | (5.7M) | |
| Depreciation | 22.2K | 4.8K | 10.2K | 249.6K | 287.0K | 301.4K | |
| Other Non Cash Items | 4.3M | (244.4K) | 3.7M | 964.1K | 1.1M | 2.0M | |
| Capital Expenditures | 2.9K | 0.0 | 220.0K | 22.9K | 26.3K | 25.0K | |
| Net Income | (7.3M) | (6.3M) | (8.2M) | (7.9M) | (7.1M) | (7.5M) | |
| End Period Cash Flow | 83.1K | 1.4M | 11.4M | 2.8M | 3.2M | 3.6M |
BioAffinity Technologies, Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to BioAffinity Technologies, or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that BioAffinity Technologies,'s price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a BioAffinity stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -1.08 | |
β | Beta against Dow Jones | 1.78 | |
σ | Overall volatility | 7.81 | |
Ir | Information ratio | -0.15 |
BioAffinity Technologies, Volatility Alert
bioAffinity Technologies, is displaying above-average volatility over the selected time horizon. bioAffinity Technologies, is a potential penny stock. Although BioAffinity Technologies, may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in bioAffinity Technologies,. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on BioAffinity instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.BioAffinity Technologies, Fundamentals Vs Peers
Comparing BioAffinity Technologies,'s fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze BioAffinity Technologies,'s direct or indirect competition across all of the common fundamentals between BioAffinity Technologies, and the related equities. This way, we can detect undervalued stocks with similar characteristics as BioAffinity Technologies, or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of BioAffinity Technologies,'s fundamental indicators could also be used in its relative valuation, which is a method of valuing BioAffinity Technologies, by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare BioAffinity Technologies, to competition |
| Fundamentals | BioAffinity Technologies, | Peer Average |
| Return On Equity | -1.52 | -0.31 |
| Return On Asset | -0.7 | -0.14 |
| Profit Margin | (1.19) % | (1.27) % |
| Operating Margin | (0.87) % | (5.51) % |
| Current Valuation | 7.35 M | 16.62 B |
| Shares Outstanding | 15.48 M | 571.82 M |
| Shares Owned By Insiders | 29.55 % | 10.09 % |
| Shares Owned By Institutions | 2.46 % | 39.21 % |
| Number Of Shares Shorted | 251.91 K | 4.71 M |
| Price To Book | 2.05 X | 9.51 X |
| Price To Sales | 0.71 X | 11.42 X |
| Revenue | 2.53 M | 9.43 B |
| EBITDA | (7.63 M) | 3.9 B |
| Net Income | (7.94 M) | 570.98 M |
| Cash And Equivalents | 214.4 K | 2.7 B |
| Cash Per Share | 0.08 X | 5.01 X |
| Total Debt | 1.58 M | 5.32 B |
| Current Ratio | 0.02 X | 2.16 X |
| Book Value Per Share | 0.30 X | 1.93 K |
| Cash Flow From Operations | (6.04 M) | 971.22 M |
| Short Ratio | 1.43 X | 4.00 X |
| Earnings Per Share | (0.91) X | 3.12 X |
| Target Price | 6.0 | |
| Number Of Employees | 75 | 18.84 K |
| Beta | 3.12 | -0.15 |
| Market Capitalization | 19.81 M | 19.03 B |
| Total Asset | 8.22 M | 29.47 B |
| Retained Earnings | (44.6 M) | 9.33 B |
| Working Capital | 1.72 M | 1.48 B |
| Net Asset | 8.22 M |
Note: Acquisition by Anderson Robert A. of 33784 shares of BioAffinity Technologies, subject to Rule 16b-3 [view details]
BioAffinity Technologies, Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as BioAffinity . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About BioAffinity Technologies, Buy or Sell Advice
When is the right time to buy or sell bioAffinity Technologies,? Buying financial instruments such as BioAffinity Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having BioAffinity Technologies, in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Biotech Thematic Idea Now
Biotech
Companies specialized in biotechnology production and delivery of pharmaceuticals services. The Biotech theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Biotech Theme or any other thematic opportunities.
| View All Next | Launch |
Check out BioAffinity Technologies, Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in BioAffinity Stock please use our How to Invest in BioAffinity Technologies, guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioAffinity Technologies,. If investors know BioAffinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioAffinity Technologies, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.91) | Revenue Per Share | Quarterly Revenue Growth 120.474 | Return On Assets | Return On Equity |
The market value of bioAffinity Technologies, is measured differently than its book value, which is the value of BioAffinity that is recorded on the company's balance sheet. Investors also form their own opinion of BioAffinity Technologies,'s value that differs from its market value or its book value, called intrinsic value, which is BioAffinity Technologies,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioAffinity Technologies,'s market value can be influenced by many factors that don't directly affect BioAffinity Technologies,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioAffinity Technologies,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if BioAffinity Technologies, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioAffinity Technologies,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.